Corcept Therapeutics Incorporated

Revenue comes from selling one medicine, booked only once it has been delivered and payment is considered likely, after subtracting rebates, discounts and expected returns owed to insurers, benefit managers and assistance programs. Almost all of what the company reports as revenue sits in this single line, and it has converted a large share of that revenue into cash while remaining profitable in every year on record.

The company scales its sales without owning the plants that make its product, since manufacturing is contracted out and its own physical footprint is limited to leased office space. Several aligned financial signals describe a structure where returns on assets and equity, and revenue generated per unit of asset, sit toward the high end of its industry, consistent with growth that does not require proportionally growing owned physical capital.

The company depends on outside manufacturers to supply its drug substance and produce and package its tablets, on outside research organizations to run its clinical trials, and on a single contracted partner to dispense its product and collect payment from insurers and other payers on its behalf. It has already shown that the party filling the dispensing and collection role can change, which points to dependency on the function rather than on one fixed counterparty. Within CompanyGraph's mapping of input industries, it draws from a small rather than broad set of upstream industries.

Patients being treated for a specific, hard-to-diagnose hormonal condition, and the relatively small group of physicians experienced enough to prescribe for it, depend on the company's medicine, though the company itself names branded and generic alternatives competing for the same patients. Beyond the patient relationship, the pharmacy partners that dispense the product and the insurers, benefit managers, government programs and charities that fund it also depend on the company as the source of supply. CompanyGraph's mapping separately places it upstream of several other industries it feeds into.

The company points to a large internally discovered library of cortisol-modulating compounds and to patents covering those compounds and how they are used as the basis of its position, a claim the company makes about itself rather than one CompanyGraph has independently tested. Holding patented, regulator-cleared chemistry against competitors is a common way of operating across this industry rather than a rare one, so this describes the stated basis for the company's position, not a judgment about whether rivals could copy it.

For the compounds still in testing, the pattern this company operates within is that a candidate earns nothing until a regulator clears it, and the company's own filings list failing to gain or keep that approval as a risk it tracks. For the medicine it already sells, though, its own account points to a narrower limit: in the most recent year it describes, output was capped less by patient need than by how much product its dispensing partner could actually get to patients, together with payer and government pricing decisions and how many physicians are experienced enough to prescribe it.

The company itself points to a concentrated operational dependency: nearly all of its revenue collection passes through one contracted pharmacy partner that both dispenses its product and collects payment from insurers, and that partner's own capacity already limited sales in the most recent year the company describes. It also names generic competition against its own lead medicine and public perception or legislation touching its key ingredient among the commercial risks it lists first, meaning pressure on the single product line that currently accounts for essentially all of its revenue is a named risk to its own business, not one CompanyGraph is inferring.

The company answers to drug regulators who must clear its products and, separately, its vendors' facilities, and it names pending legal and government inquiries touching statements it made about a pipeline drug's application and about how it sells, promotes and seeks reimbursement for its marketed medicine. It also names tariff and trade pressure on the materials and services it and its vendors use, and public attention and possible legislation around its key ingredient, alongside broader insurance and government pricing rules, as pressures on its business.